Cancer Research

PetScreen Supports Morris Animal Foundation Canine Cancer Campaign; Co-Sponsors Two Canine Cancer Studies

DENVER, November 1 /PRNewswire/-- PetScreen, http://www.pet-screen.com, a U.K.-based company providing screening for cancer and other diseases attacking pets, has made a generous donation to Morris Animal Foundation (MAF) in the nonprofit's global ef ...

Article - Anna Ohlden - Nov 1 2007 - 12:26pm

Nanotubes Embedded In Tumors Destroy Liver Cancer

Cancer cells treated with carbon nanotubes can be destroyed by non-invasive radio waves that heat up the nanotubes while sparing untreated tissue, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center and Rice University ...

Article - News Staff - Nov 1 2007 - 3:09pm

ThromboGenics And BioInvent Announce Publication Of Exciting Data On A Novel Class Of Angiogenesis Inhibitors In Cell

LEUVEN, Belgium and LUND, Sweden, November 2 /PRNewswire/--- Novel Anti-PlGF Antibody, TB-403, Being Developed by ThromboGenics and BioInvent for Cancer Expected to Enter the Clinic Later This Year ...

Article - Anna Ohlden - Nov 2 2007 - 1:04am

Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy In Treatment Of Chronic Hepatitis C

BASEL, Switzerland, November 2 /PRNewswire/--- Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C (HCV), has shown promising antiviral efficacy when given in combination with PEGA ...

Article - Anna Ohlden - Nov 2 2007 - 7:19am

EpiCept To Host Third Quarter 2007 Conference Call And Webcast On November 7, 2007

TARRYTOWN, New York, November 3 /PRNewswire/-- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will host a conference call to discuss third quarter 2007 results and provide a business update on Wednesday, November 7, 200 ...

Article - Anna Ohlden - Nov 3 2007 - 1:23am

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior To Clopidogrel In Reducing Risk Of Heart Attack

TOKYO and INDIANAPOLIS, November 4 /PRNewswire/--- Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI ...

Article - Anna Ohlden - Nov 4 2007 - 8:42am

Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel

TOKYO and INDIANAPOLIS, November 4 /PRNewswire/--- Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is ...

Article - Anna Ohlden - Nov 4 2007 - 8:42am

First Systemic Therapy For Fatal RDEB Childhood Disease

Recessive dystrophic epidermolysis bullosa (RDEB)is a disease where children lack a protein that anchors skin to the body, resulting in fragile skin that tears off with little movement or friction. They suffer painful wounds and must be bandaged at all tim ...

Article - News Staff - Nov 4 2007 - 10:29am

Mapping The Genetic Landscape Of Lung Cancer

An international team of scientists today announced the results of a systematic effort to map the genetic changes underlying lung cancer, the world’s leading cause of cancer deaths. The research provides a comprehensive view of the abnormal genetic landsca ...

Article - News Staff - Nov 4 2007 - 5:57pm

EpiCept Corporation Reports Third Quarter 2007 Operating And Financial Results

TARRYTOWN, New York, November 5 /PRNewswire/--- Encouraging regulatory progress on Ceplene in Europe ...

Article - Anna Ohlden - Nov 5 2007 - 12:22am